AU Patent

AU2008216083B2 — Fixed drug ratios for treatment of hematopoietic cancers and proliferative disorders

Assigned to Jazz Pharmaceuticals Therapeutics Inc · Expires 2014-02-06 · 12y expired

What this patent protects

Provided herein are methods for treating cancer by administering a pharmaceutical composition comprising a fixed, non-antagonistic molar ratio of cytarabine and an anthracycline. Such methods are particularly useful in the treatment of patients with advanced hematologic cancers o…

USPTO Abstract

Provided herein are methods for treating cancer by administering a pharmaceutical composition comprising a fixed, non-antagonistic molar ratio of cytarabine and an anthracycline. Such methods are particularly useful in the treatment of patients with advanced hematologic cancers or proliferative disorders.

Drugs covered by this patent

Patent Metadata

Patent number
AU2008216083B2
Jurisdiction
AU
Classification
—
Expires
2014-02-06
Drug substance claim
No
Drug product claim
No
Assignee
Jazz Pharmaceuticals Therapeutics Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.